Radcliffe Capital Management’s Apexigen, Inc. Common Stock APGN Stock Holding History

Radcliffe Capital Management’s Portfolio APGN Stock Details APGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-131,765	Closed	-$1.34M	–	1215
2022 Q2	$1.34M	Hold	131,765	–	–	0.03%	849
2022 Q1	$1.33M	Hold	131,765	–	–	0.03%	832
2021 Q4	$1.32M	Hold	131,765	–	–	0.03%	725
2021 Q3	$1.31M	Hold	131,765	–	–	0.04%	614
2021 Q2	$1.31M	Hold	131,765	–	–	0.04%	639
2021 Q1	$1.29M	Buy	+131,765	New	+$1.32M	0.05%	530

Other funds holding APGN

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Yu Fan $97M AUM 57.2% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Radcliffe Capital Management's APGN Position: Q3 2022 in Review

Radcliffe Capital Management sold out of Apexigen, Inc. Common Stock (APGN) in Q3 2022, closing a stake of 131,765 shares — an estimated $1.34M sold.

Radcliffe Capital Management first reported a position in APGN in Q1 2021 and held it in 6 quarters. The position peaked at $1.34M in Q2 2022. 18 funds tracked by Wall St. Rank hold APGN as of Q3 2022.

Radcliffe Capital Management reported no remaining Apexigen, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Radcliffe Capital Management sold 131,765 Apexigen, Inc. Common Stock shares in Q3 2022, an estimated $1.34M.
Radcliffe Capital Management first reported a position in Apexigen, Inc. Common Stock in Q1 2021 and held it in 6 quarters.
Radcliffe Capital Management's Apexigen, Inc. Common Stock position peaked at $1.34M in Q2 2022.
18 funds tracked by Wall St. Rank held Apexigen, Inc. Common Stock as of Q3 2022.

Based on Radcliffe Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.